Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113957 · ClinicalTrials.gov registry record · Phase 2
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01113957 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 168 participants.
The verdict
NCT01113957, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.
Interventions
- DRUG pegylated liposomal doxorubicin
- DRUG temozolomide
- DRUG ABT-888
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113957
The ClinicalTrials.gov registry entry for NCT01113957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pegylated liposomal doxorubicin is the first listed.
NCT01113957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01113957 about?
NCT01113957 is a clinical study titled "A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer". The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.
What is the current status of trial NCT01113957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2010-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01113957?
The interventions under investigation include: pegylated liposomal doxorubicin (DRUG), temozolomide (DRUG), ABT-888 (DRUG).
Who is sponsoring clinical trial NCT01113957?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.